Advancements in Gastrointestinal Health – A Comprehensive Update Anahat Kaur, MD

- Hematology and Medical Oncology
- Charleston Area Medical Center, WV





Esophageal Squamous Cell Carcinoma

GEJ/Gastric Adenocarcinoma

- **GLOW**: Zolbetuximab + CAPOX in CLDN 18.2 positive advanced gastric and GEJ cancer
- on or after a trastuzumab-containing regimen

Pancreatic Cancer

- induction treatment for first-line treatment of metastatic pancreatic cancer

Neuroendocrine Tumors

neuroendocrine tumors

Colorectal Cancer

- chemoradiation, followed by total mesorectal excision for treatment of locally advanced rectal cancer.
- FRESCO 2: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer
- Updates on role of ctDNA from GI ASCO 2024

• SKYSCRAPER - 08: Phase III study of first-line tiragolumab + atezolizumab and chemotherapy in patients with advanced esophageal SCC

• DESTINY - Gastric 02: TDxd in patients in the USA and Europe with HER2-positive advanced gastric or GEJ cancer with disease progression

• NAPOLI-3: Phase 3 study NALIRIFOX versus gemcitabine + nab-paclitaxel in treatment-naïve patients with metastatic pancreatic cancer • ALPACA: Alternating application of gemcitabine/nab-paclitaxel and Gem monotherapy or continuous application of Gem/nab-Pac after


• NETTER 2: ¹⁷⁷Lu-DOTATATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic

• **PROSPECT**: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of

	West Virginia Oncology
\wedge	Society

SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line tiragolumab + atezolizumab and chemotherapy in patients with esophageal squamous cell carcinoma

Patients were enrolled across Asia at 67 centers in mainland China, Hong Kong, Taiwan, South Korea, and Thailand






Chih-Hung Hsu, et al. Journal of Clinical Oncology 2024 42:3_suppl, 245-245 Figures are property of the study authors, licensed by ASCO.



IRF-assessed PFS per RECIST v1.1 (primary endpoint)




Chih-Hung Hsu, et al. Journal of Clinical Oncology 2024 42:3_suppl, 245-245 Figures are property of the study authors, licensed by ASCO.

	Tiragolumab + atezolizumab + cisplatin + paclitaxel (n=229)	Placebo + cisplatin + paclitaxel (n=232)	
Patients with events, %	150 (65.5)	193 (83.2)	
Median PFS, months (95% CI)	6.2 (5.7, 7.2)	5.4 (4.4, 5.5)	
Stratified HR (95% CI)	0.56 (0.45, 0.70)		
P-value (stratified log-rank)	P<0.0001		



Final analysis of OS (primary endpoint)



Chih-Hung Hsu, et al. Journal of Clinical Oncology 2024 42:3_suppl, 245-245 Figures are property of the study authors, licensed by ASCO.




GLOW: Zolbetuximab + CAPOX in CLDN18.2+ G/GEJ Cancer

Global, double-blind, placebo-controlled, randomized phase III study

Stratified by region (Asia vs non-Asia), organs w/mets (0-2 vs \geq 3), prior gastrectomy (yes vs no)

Patients with CLDN18.2+ (≥ 75% by IHC) HER2unresectable/metastatic G/GEJ adenocarcinoma, no prior CT (N = 500)



* Zolbetuximab dosed initially as 800 mg/mm² IV followed by 600 mg/mm³ IV Q3W. CAPOX dosed as 21d cycles of oxaliplatin 130 mg/mm² IV up to 8 cycles and capecitabine at investigator's discretion cycle 9+.

Primary endpoint: IRC-assessed PFS


Secondary endpoints: OS, ORR, DOR, safety, PK, QoL

Shah. et al. Nat Med 2023.

Figures are property of the study authors, licensed by ASCO.




Primary End Point: PFS by Independent Review Committee



Shah, et al. Nat. Med. 2023 Figures are property of the study authors, licensed by ASCO.



Key Secondary End Point: OS




Shah, et al. Nat. Med. 2023 Figures are property of the study authors, licensed by ASCO.



DESTINY-Gastric02 Study Design


An open-label, multicenter phase 2 study in Western patients with HER2+ gastric or GEJ cancer who had progressed on a trastuzumab-containing regimen (NCT04014075)



A high proportion of patients receiving trastuzumab deruxtecan in this study reached the primary endpoint of confirmed objective response rate by independent central review (33 [42%; 95% CI 30·8–53·4] of 79; Nov 8, 2021 data cutoff)

Van Cutsem E et. al, Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14. PMID: 37329891.






Van Cutsem E et. al, Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14. PMID: 37329891.



NAPOLI 3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma



Zev A. Wainberg, et al. Journal of Clinical Oncology 2023 41:4_suppl, LBA661-LBA661 Figures are property of the study authors, licensed by ASCO.

NALIRIFOX

Liposomal irinotecan 50 mg/m² + 5-FU 2400 mg/m² + LV 400 mg/m² + oxaliplatin 60 mg/m² Days 1 and 15 of a 28-day cycle

Gem+NabP


Gem 1000 mg/m² + NabP 125 mg/m² Days 1, 8 and 15 of a 28-day cycle Tumor assessment every 8 weeks per RECIST v1.1^a

Treatment until disease progression, unacceptable toxicity or study withdrawal^b

Follow-up every 8 weeks until death or study end^c



NAPOLI 3: mPFS per investigator (ITT population)




NAPOLI 3: mOS (ITT population)

100 (%) SO

No. at risk: NALIRIFOX 383

Zev A. Wainberg, et al. Journal of Clinical Oncology 2023 41:4_suppl, LBA661-LBA661 Figures are property of the study authors, licensed by ASCO. p value < 0.0001

7+++	
22	24
4	0



FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma

f Share	🗙 Post	i
---------	--------	---

On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.

<u>View full prescribing information for Onivyde</u>.

Efficacy was evaluated in NAPOLI 3 (NCT04083235), a randomized, multicenter, openlabel, active-controlled trial in 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy in the metastatic setting. Randomization was stratified by region, liver metastases, and ECOG performance status. Patients were randomized (1:1) to receive one of the following treatments:

in Linkedin	🔽 Email	🖨 Print
--------------------	---------	---------




Alternating Gemcitabine/nab-Paclitaxel and Gemcitabine ALPACA Trial (AIO-PAK-0114)

n = 325

Key inclusion criteria:

- Age ≥18 years •
- Confirmed PDAC not previously treated in the metastatic setting
- ≥1 lesion measurable by CT/MRI according to RECIST v1.1
- KPS of 70-100%



Stratification factors: KPS 70-80% vs. 90-100% Presence vs. no presence of liver metastasis


Klara Dorman, et al. Journal of Clinical Oncology 2024 42:3_suppl, 605-605 Figures are property of the study authors, licensed by ASCO.

nab-Paclitaxel 125 mg/m² on days 1, 8, 15 of a 28-day cycle

Gemcitabine 1000 mg/m² on days 1, 8, 15 of a 28-day cycle


CT/MRI





Klara Dorman, et al. Journal of Clinical Oncology 2024 42:3_suppl, 605-605 Figures are property of the study authors, licensed by ASCO.


Efficacy and Safety of [¹⁷⁷Lu]Lu-DOTA-TATE in Newly Diagnosed Patients with Advanced Grade 2 and Grade 3, Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: Primary Analysis of the Phase 3 Randomized NETTER-2 Study



Simron Singh, et al. Journal of Clinical Oncology 2024 42:3_suppl, LBA588-LBA588 Figures are property of the study authors, licensed by ASCO.



¹⁷⁷Lu-DOTATATE showed significant improvement in primary PFS endpoint



Simron Singh, et al. Journal of Clinical Oncology 2024 42:3_suppl, LBA588-LBA588 Figures are property of the study authors, licensed by ASCO.

OTATATE arm		¹⁷⁷ Lu- DOTATATE arm n=151	High dose octreotide arm n=75
	PFS median, months (95% CI)	22.8 (19.4, NE)	<mark>8.5</mark> (7.7, 13.8)
	Stratified HR (95% CI) p-value	0.276 (0.18 <0.00	
e octreotide arm	Number of events, n (%) Progression Death	55 (36) 47 (31) 8 (5)	46 (61) 41 (55) 5 (7)
26 28 30 32 34 36	disease progre		in
19139420110000	the ¹⁷⁷ Lu-DOTA the high dose	TATE arm vers octreotide arm	




PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

PROSPECT


Randomization

1:1

N=1128




Schrag et al. N Engl J Med 2023;389:322-334 Dapra V et al. Int. J. Mol. Sci. 2023, 24, 12159.











Noninferiority required that the upper limit of the two-sided 90.2% CI not exceed 1.29.



Schrag et al. N Engl J Med 2023;389:322-334

Disease-free Survival



CONCLUSIONS

In patients with locally advanced rectal cancer amenable to sphincter-sparing surgery, neoadjuvant FOLFOX chemotherapy with selective use of chemoradiotherapy was noninferior to neoadjuvant chemoradiotherapy for disease-free survival, and nearly 90% of patients in the FOLFOX group were able to avoid chemoradiotherapy.





Fruguintinib versus placebo in patients with refractory metastatic double-blind, phase 3 study

Patient Eligibility


- Prior treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild type, an anti-EGFR therapy
- Progression on, or intolerance to, TAS-102 and/or regoratenib
- Prior treatment with an immune checkpoint inhibitor or BRAF inhibitor if indicated

Stratification Factors


- Prior therapy (TAS-102 vs regorafenib vs TAS-102 and regorafenib)
- RAS mutational status (wild-type vs mutant)
- Duration of metastatic disease (≤18 months vs >18 months)

Note: To ensure the patient population is reflective of clinical practice, the number of patients treated with prior regoratenib was limited to 344 patients (50%)

colorectal cancer (FRESCO-2): an international, multicentre, randomised,







Dasari A, et al. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. PMID: 37331369.



FDA approves fruquintinib in refractory metastatic colorectal cancer



On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.


Linkedin 🗹 Email 🖨 Print





Role of ctDNA in Colorectal Cancer – Updates from GI ASCO 2024

Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study



Pashtoon Murtaza Kasi et al. Journal of Clinical Oncology 2024 42:3_suppl, 9-9

Stages II-III

O status	MRD-negative	MRD-positive
of events (%)	38/530 (7.17)	55/93 (59.14)
S post surgery, 95% CI)	<mark>91.59</mark> (88.38-93.94)	29.86 (13.26-48.54)
S post surgery, hs (95%)	Not reached	15.98 (13.77-20.22)

	1	Т	Т	Т	Т	Т	Т	Т		-
12	0	1	32	2	1	44	1	1	156	

0 0

MRD window:


2-12 weeks post-surgery, before the start of adjuvant chemotherapy (ACT)

Surveillance window: >2 weeks post-ACT or >12 weeks post-surgery if on observation



Benefit from ACT observed in MRD-positive but not MRD-negative patients MRD-negative patients

MRD-positive patients



Adjuvant strategy	ACT	Observation	Adjuvant strategy	ACT	Observation
Numbers of events (%)	47/85 (55.29)	8/8 (100)	Numbers of events (%)	18/296 (6.08)	20/234 (8.55)
2-year DFS post surgery, % (95% CI)	42.44 (31.55-52.91)	12.50 (0.66-42.27)	2-year DFS post surgery, % (95% CI)	93.70 (90.03-96.05)	<mark>90.39</mark> (85.38-93.75
Median DFS post surgery, months (95%)	17.78 (14.37-not reached)	7.52 (3.52-15.88)	Median DFS post surgery, months (95%)	Not reached	Not reached

ASCO Gastrointestinal Cancers Symposium

#GI24

PRESENTED BY: Pashtoon Kasi, MD


Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org.





ctDNA-positivity during surveillance is predictive of inferior DFS regardless of adjuvant therapy (ACT or observation)

Patients receiving ACT



cibitA status (surveinance)	CIDIA-negative	cibitA-positive
Numbers of events (%)	7/329 (2.13)	59/78 (75.64)
2-year DFS post end of ACT, % (95% CI)	97.58 (94.96-98.84)	22.56 (13.49-33.08)
Median DFS post end of ACT, months (95%)	Not reached	9.70 (7.43-12.32)

ASCO Gastrointestinal Cancers Symposium

#GI24

PRESENTED BY: Pashtoon Kasi, MD

Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org.


ctDNA status (surveillance)	ctDNA-negative	ctDNA-positive
Numbers of events (%)	6/225 (2.67)	21/23 (91.30)
2-year DFS post surgery, % (95% Cl)	96.60 (92.44-98.49)	13.04* (3.27-29.72)
Median DFS post surgery, months (95%)	Not reached	9.44 (7.86-17.03)

*Most recurrences occurred within the1st year.





Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study



Primary objective (phase II):

Compare rates of ctDNA clearance between ctDNA (+) cohorts at 6 months after randomization.




16 participants with "ctDNA detected" status at baseline

Clearance of ctDNA at 6 months among ctDNA(+) participants at baseline was observed in:

- Arm 1 (surveillance): 3 of 7 (43%, 95% Cl 10 82%) participants Arm 2 (chemotherapy): 1 of 9 patients (11%, 95% CI 0.3 - 48%) participants ٠

Study was discontinued early due to futility.







Take Home Points on ctDNA in Colorectal cancer



Given the poor prognostic risk of positive ctDNA and early data on improvement in short-term outcomes with adjuvant chemotherapy, consider use of a positive ctDNA test to escalate treatment in Stage II/III colorectal cancer patients.



We do *not* have enough evidence at this time to use a negative ctDNA test to de-escalate therapy.



Use of ctDNA for monitoring cancer recurrence requires shared decision-making with the patient.

